

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the Additional Assignee previously recorded on Reel 009043 Frame 0205. Assignor(s) hereby confirms the The University of Texas Southwestern Medical Center at Dallas was inadvertently left off original recordation sheet..

CONVEYING PARTY DATA

Name	Execution Date
Derk J BERGSMA	02/10/1998
David P BROOKS	02/13/1998
Miklos GELLAI	02/18/1998
Shelagh WILSON	02/18/1998
Masahi YANAGISAWA	02/26/1998

RECEIVING PARTY DATA

Name:	University of Texas Southwestern Medical Center at Dallas
Street Address:	5323 Harry Hines Boulevard
City:	Dallas
State/Country:	TEXAS
Postal Code:	75235

Name:	SmithKline Beecham Corporation
Street Address:	One Franklin Plaza
City:	Philadelphia
State/Country:	PENNSYLVANIA
Postal Code:	19103

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	6001963

CORRESPONDENCE DATA

Fax Number: (610)270-5253

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

CH \$40.00 6001963

Phone: 610-270-7568
Email: US_CIPKOP@GSK.com
Correspondent Name: GlaxoSmithKline
Address Line 1: 709 Swedeland Road
Address Line 2: UW2220
Address Line 4: King of Prussia, PENNSYLVANIA 19406

ATTORNEY DOCKET NUMBER:

ATG50037/SBC

NAME OF SUBMITTER:

Arlene E Cannon

Total Attachments: 15

source=atg50037_assignment#page1.tif
source=atg50037_assignment#page2.tif
source=atg50037_assignment#page3.tif
source=atg50037_assignment#page4.tif
source=atg50037_assignment#page5.tif
source=atg50037_assignment#page6.tif
source=atg50037_assignment#page7.tif
source=atg50037_assignment#page8.tif
source=atg50037_assignment#page9.tif
source=atg50037_assignment#page10.tif
source=atg50037_assignment#page11.tif
source=atg50037_assignment#page12.tif
source=atg50037_assignment#page13.tif
source=atg50037_assignment#page14.tif
source=atg50037_assignment#page15.tif

MRB 3-12-98

03-23-1998

58/40

ATTORNEY DOCKET NO. AT

Form PTO-1595



100668691

DEPARTMENT OF COMMERCE
Patent and Trademark Office

RECORDATION FORM COVER SHEET
PATENTS ONLY

Commissioner of Patents. Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies)</p> <p>Derk J. Bergsma, David P. Brooks, Miklos Gellai, Shelagh Wilson, and Masashi Yanagisawa</p> <p>Additional names of conveying party(ies) attached? [] yes [X] no</p>	<p>2. Name and address of receiving party(ies)</p> <p>SmithKline Beecham Corporation One Franklin Plaza Philadelphia, PA 19103 United States of America</p> <p>Additional name(s) and addresses attached? [] yes [X] no</p>
--	--

3. Description of the interest conveyed:

<input checked="" type="checkbox"/> Assignment, please record and return	<input type="checkbox"/> Merger
<input type="checkbox"/> Security Agreement	<input type="checkbox"/> Change of Name
<input type="checkbox"/> Other	

Execution date of Assignment: February 10, 13, 18, and 26 1998

4. Application number(s) or patent number(s). Additional Sheets attached? Yes No

A. Patent Application No.(s) 08/938,548;SEPTEMBER 26, 1997	B. Patent No.(s)
---	------------------

If this document is being filed together with a new application, the execution date of the application is
February 10, 13, 18, and 26 1998

<p>5. Name and address of party to whom correspondence concerning documents should be mailed:</p> <p>Elizabeth J. Hecht SmithKline Beecham Corporation Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939</p>	<p>6. Total number of applications and patents involved <u>1</u>.</p> <p>7. Total Fee (37 C.F.R. 3.41) <u>\$40.00</u></p> <p>8. Please charge this fee to deposit account No. <u>19-2570</u>.</p> <p>The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to our Deposit Account No. 19-2570.</p>
--	--

DO NOT USE THIS SPACE

9. Statement and Signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Elizabeth J. Hecht	<u>Elizabeth J. Hecht</u>	March 12, 1998
Name of Person Signing	Signature	Date

Total number of pages including cover sheet, attachments and document: 7

document7

03/23/1998 DCDATES 00000105 DAW:192570 08939093
01 FC:581 40.00 CH

Docket No.: ATG50037-3

ASSIGNMENT

WHEREAS we, Derk Jon Bergsma of 271 Irish Road, Berwyn, PA 19312, a citizen of United States of America; David P. Brooks of 527 Beaumont Circle, West Chester, PA 19380, a citizen of the United States of America; Miklos Gellai of 332 Conestoga Road, Devon, PA 19333, a citizen of the United States of America; Shelagh Wilson of Becketts Bramfield, Herford, Hertfordshire, SG14QQJ, a citizen of the United Kingdom; and Masashi Yanagisawa of 4301 Northaven Road, Dallas, Texas 75229, a citizen of Japan have made an invention entitled:

"A Novel Ligand of the Neuropeptide Receptor HFGAN72"

for which on Mar 10, 13 & 18 1998 we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a) or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by SmithKline Beecham Corporation, a corporation organized under the laws of the Commonwealth of Pennsylvania and having its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19103, and University of Texas Southwestern Medical Center at Dallas, and having its principal place of business at 5323 Harry Hines Boulevard, Dallas, Texas 75235-9008, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said SmithKline Beecham Corporation and University of Texas Southwestern Medical Center at Dallas, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a) or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

We further assign to the said SmithKline Beecham Corporation and University of Texas Southwestern Medical Center at Dallas the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;

And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.

Signed at King of Prussia

Derk Jon Bergsma
Derk Jon Bergsma

Date: 02/10/98

Commonwealth of Pennsylvania)

) ss.:

County of Montgomery)

Before me, a Notary Public, personally appeared Derk Jon Bergsma known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this 10 day of February, 1998



Arlene E. Cannon

Signed at King of Prussia PA

David P. Brooks
David P. Brooks

Date: 2/18/98


Commonwealth of Pennsylvania)

) ss.:

County of Montgomery)

Before me, a Notary Public, personally appeared David P. Brooks known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this 18 day of February, 1998



Arlene E. Cannon

Signed at King of Prussia

Miklos Gellai
Miklos Gellai

Date 02/18/98

Commonwealth of Pennsylvania)

) ss.:

County of Montgomery)

Before me, a Notary Public, personally appeared Miklos Gellai known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

NOTARIAL SEAL
ARLENE E. CANNON, Notary Public
Upper Merion Twp., Montgomery County
My Commission Expires May 21, 2001

Witness my hand and seal this 18 day of February, 1998

Arlene Cannon

Signed at Holow UK

Shelagh Wilson
Shelagh Wilson

Date 13 Feb 98

Signed at _____

Masashi Yanagisawa

Date _____

Docket No.: ATG50037-3

ASSIGNMENT

WHEREAS we, Derk Jon Bergsma of 271 Irish Road, Berwyn, PA 19312, a citizen of United States of America; David P. Brooks of 527 Beaumont Circle, West Chester, PA 19380, a citizen of the United States of America; Miklos Gellai of 332 Conestoga Road, Devon, PA 19333, a citizen of the United States of America; Shelagh Wilson of Becketts Bramfield, Herford, Hertfordshire, SG14QQJ, a citizen of the United Kingdom; and Masashi Yanagisawa of 4301 Northaven Road, Dallas, Texas 75229, a citizen of Japan have made an invention entitled:

"A Novel Ligand of the Neuropeptide Receptor HFGAN72"

for which on Feb. 26, 1998 we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a) or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by SmithKline Beecham Corporation, a corporation organized under the laws of the Commonwealth of Pennsylvania and having its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19103, and University of Texas Southwestern Medical Center at Dallas, and having its principal place of business at 5323 Harry Hines Boulevard, Dallas, Texas 75235-9008, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said SmithKline Beecham Corporation and University of Texas Southwestern Medical Center at Dallas, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a) or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

We further assign to the said SmithKline Beecham Corporation and University of Texas Southwestern Medical Center at Dallas the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;

And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.

Signed at _____

Derk Jon Bergsma

Date: _____

Commonwealth of Pennsylvania)

) ss.:

County of Montgomery)

Before me, a Notary Public, personally appeared Derk Jon Bergsma known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this _____ day of _____, 1997.

Signed at _____

David P. Brooks

Date: _____

Commonwealth of Pennsylvania)

) ss.:

County of Montgomery)

Before me, a Notary Public, personally appeared David P. Brooks known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this _____ day of _____, 1997.

Signed at _____

Date _____

Miklos Gellai

Commonwealth of Pennsylvania)
) ss.:

County of Mongtomery)

Before me, a Notary Public, personally appeared Miklos Gellai known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.


Witness my hand and seal this _____ day of _____, 1997.

Signed at _____

Date _____

Shelagh Wilson

Signed at Dallas, TX



Masashi Yanagisawa

Date 2-26-98

Docket No.: ATG50037-2

ASSIGNMENT

WHEREAS we, Derk Jon Bergsma of 271 Irish Road, Berwyn, PA 19312, a citizen of United States of America; David P. Brooks of 527 Beaumont Circle, West Chester, PA 19380, a citizen of the United States of America; Miklos Gellai of 332 Conestoga Road, Devon, PA 19333, a citizen of the United States of America; Shelagh Wilson of Becketts Bramfield, Herford, Hertfordshire, SG14QQJ, a citizen of the United Kingdom; and Masashi Yanagisawa of 4301 Northaven Road, Dallas, Texas 75229, a citizen of Japan have made an invention entitled:

"A Novel Ligand of the Neuropeptide Receptor HFGAN72"

for which on Feb. 10, 13 + 18 1998 we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a) or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by SmithKline Beecham Corporation, a corporation organized under the laws of the Commonwealth of Pennsylvania and having its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19103, and University of Texas Southwestern Medical Center at Dallas, and having its principal place of business at 5323 Harry Hines Boulevard, Dallas, Texas 75235-9008, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said SmithKline Beecham Corporation and University of Texas Southwestern Medical Center at Dallas, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a) or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

We further assign to the said SmithKline Beecham Corporation and University of Texas Southwestern Medical Center at Dallas the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;

And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.

Signed at King of Prussia, U.S.A.

Miklos Gellai
Miklos Gellai

Date 18 Feb. 98


Commonwealth of Pennsylvania)

) ss.:

County of Montgomery)

Before me, a Notary Public, personally appeared Miklos Gellai known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this 18 day of February, 1998.



Arlene E Cannon

Signed at Haltom

Shelagh Wilson
Shelagh Wilson

Date 13 Feb 98

Signed at _____

Masashi Yanagisawa

Date _____

Docket No.: ATG50037-2

ASSIGNMENT

WHEREAS we, Derk Jon Bergsma of 271 Irish Road, Berwyn, PA 19312, a citizen of United States of America; David P. Brooks of 527 Beaumont Circle, West Chester, PA 19380, a citizen of the United States of America; Miklos Gellai of 332 Conestoga Road, Devon, PA 19333, a citizen of the United States of America; Shelagh Wilson of Becketts Bramfield, Herford, Hertfordshire, SG14QQJ, a citizen of the United Kingdom; and Masashi Yanagisawa of 4301 Northaven Road, Dallas, Texas 75229, a citizen of Japan have made an invention entitled:

"A Novel Ligand of the Neuropeptide Receptor HFGAN72"

for which on Nov. 26, 1998 we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a) or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by SmithKline Beecham Corporation, a corporation organized under the laws of the Commonwealth of Pennsylvania and having its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19103, and University of Texas Southwestern Medical Center at Dallas, and having its principal place of business at 5323 Harry Hines Boulevard, Dallas, Texas 75235-9008, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said SmithKline Beecham Corporation and University of Texas Southwestern Medical Center at Dallas, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a) or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

We further assign to the said SmithKline Beecham Corporation and University of Texas Southwestern Medical Center at Dallas the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;

And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.

Signed at _____

_____)
Derk Jon Bergsma

Date: _____

Commonwealth of Pennsylvania)
) ss.:
County of Montgomery)

Before me, a Notary Public, personally appeared Derk Jon Bergsma known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this _____ day of _____, 1997.

Signed at _____

_____)
David P. Brooks

Date: _____

Commonwealth of Pennsylvania)
) ss.:
County of Montgomery)

Before me, a Notary Public, personally appeared David P. Brooks known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this _____ day of _____, 1997.

Signed at _____

Date _____

Miklos Gellai

Commonwealth of Pennsylvania)
) ss.:
County of Montgomery)

Before me, a Notary Public, personally appeared Miklos Gellai known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this _____ day of _____, 1997.


Signed at _____

Date _____

Shelagh Wilson

Signed at Dallas, TX

Date 2-26-98



Masashi Yanagisawa